| Q38250719 | Antihyperglycaemic therapies and cancer risk |
| Q35043204 | Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting |
| Q38012891 | Association between pioglitazone and urothelial bladder cancer |
| Q27002540 | Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q33792658 | Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy |
| Q38058381 | Examining the safety of PPAR agonists - current trends and future prospects |
| Q91671552 | Functional network analysis of gene-phenotype connectivity based on pioglitazone |
| Q36942266 | Interpreting adverse signals in diabetes drug development programs |
| Q33588852 | Latest insights into the risk of cancer in diabetes |
| Q33855157 | Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. |
| Q38061184 | Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies |
| Q55517521 | Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model. |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q34324440 | Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies |
| Q38721611 | Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis |
| Q38282651 | Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit |
| Q36428100 | Pioglitazone in clinical practice: where are we now? |
| Q45974480 | Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. |
| Q55406042 | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. |
| Q87321704 | Pioglitazone: No Longer a Worry for Bladder Cancer? |
| Q37583052 | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. |
| Q44980532 | Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study |
| Q38122640 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? |
| Q35603965 | Successful drug development despite adverse preclinical findings part 2: examples |
| Q28478349 | The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL |
| Q38275171 | The ongoing pursuit of neuroprotective therapies in Parkinson disease |
| Q36001145 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q34065266 | Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis |
| Q34315432 | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. |
| Q38250185 | Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease |